Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China

被引：0
|
作者：
Yake Lou
Tianyang Hu
Jing Huang
机构：
[1] The Second Affiliated Hospital of Chongqing Medical University,Department of Cardiology
[2] The Second Affiliated Hospital of Chongqing Medical University,Precision Medicine Center
来源：
American Journal of Cardiovascular Drugs | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：47 / 57
页数：10
相关论文
共 50 条
  • [41] PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE®) IN THE TREATMENT OF PATIENTS WITH HEART FAILURE (HF) WITH PRESERVED EJECTION FRACTION (HFPEF) IN FRANCE, BASED ON EMPEROR-PRESERVED CLINICAL TRIAL
    Levy, P.
    Lamblin, N.
    Groyer, H.
    Chollet, J.
    Tardu, J.
    Linden, S.
    Fauchier, L.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S83 - S83
  • [42] Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review
    Rezapour, Aziz
    Tashakori-Miyanroudi, Mahsa
    Haghjoo, Majid
    Barzegar, Mohammad
    Tatarpour, Parvin
    Souresrafil, Aghdas
    Gorji, Hassan Abolghasem
    Yousefzadeh, Negar
    Sheikhy-Chaman, Mohammadreza
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2023, 23 (02) : 127 - 144
  • [43] Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review
    Aziz Rezapour
    Mahsa Tashakori-Miyanroudi
    Majid Haghjoo
    Mohammad Barzegar
    Parvin Tatarpour
    Aghdas Souresrafil
    Hassan Abolghasem Gorji
    Negar Yousefzadeh
    Mohammadreza Sheikhy-Chaman
    [J]. American Journal of Cardiovascular Drugs, 2023, 23 : 127 - 144
  • [44] COST-EFFECTIVENESS OF DAPAGLIFLOZIN PLUS STANDARD TREATMENT COMPARED TO STANDARD TREATMENT FOR THE MANAGEMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN COLOMBIA
    Rojas, Gil Y.
    Lasalvia, P.
    Pena, Garcia A. A.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S92 - S92
  • [45] Comparative Cost-Effectiveness of Sacubitril-Valsartan, Dapagliflozin, and Empagliflozin in Heart Failure With Reduced Ejection Fraction
    Parikh, Neil U.
    Dixit, Neal
    Ziaeian, Boback
    Fonarow, Gregg C.
    [J]. CIRCULATION, 2022, 146
  • [46] Cost-Effectiveness of Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: the DELIVER Trial
    Lin, Lu
    Xiu, Qiu-ping
    Liu, Fei
    Zhang, Hou-jing
    Chen, Yi-feng
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2023,
  • [47] Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States
    Nechi, Regina Nwamaka
    Rane, Amey
    Karaye, Rukayyah M.
    Ndikumukiza, Cyrille
    Alsahali, Saud
    Jatau, Abubakar I.
    Zoni, Cesar Rodrigo
    Alanzi, Abdullah
    Karaye, Ibraheem M.
    Yunusa, Ismaeel
    [J]. CLINICAL THERAPEUTICS, 2023, 45 (07) : 627 - 632
  • [48] COMPARATIVE COST EFFECTIVENESS OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN IN HEART FAILURE WITH REDUCED EJECTION FRACTION
    Gravlee, E.
    Prajapati, P.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S409 - S410
  • [49] Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal
    Borges, Margarida
    Afonso-Silva, Marta
    Laires, Pedro A.
    Gouveia, Miguel
    Alarcao, Joana
    Ascencao, Raquel
    Costa, Joao
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (02) : 199 - 205
  • [50] Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
    McMurray, John J. V.
    Trueman, David
    Hancock, Elizabeth
    Cowie, Martin R.
    Briggs, Andrew
    Taylor, Matthew
    Mumby-Croft, Juliet
    Woodcock, Fionn
    Lacey, Michael
    Haroun, Rola
    Deschaseaux, Celine
    [J]. HEART, 2018, 104 (12) : 1006 - 1013
12345